Client Challenge

The client developed a dengue virus (DENV) vaccine, which the European Medicines Agency approved, based on Phase 3 clinical trial data. Subsequently, the client needed to evaluate the vaccine’s real-world impact in terms of reducing hospitalizations due to dengue virus infection in endemic regions where vaccination is implemented.

Our solution

We designed a controlled Interrupted Time Series study using linked surveillance data to compare trends in laboratory-confirmed DENV hospitalizations before and after vaccine introduction while meticulously addressing population-level biases. Our team of epidemiologists and statisticians developed an appropriate methodological approach to answer the client’s research challenge. To support the study, we collaborated with a local dengue virus expert in Brazil who served as Principal Investigator. Together, we conducted a feasibility assessment of linked databases, and identified suitable municipalities for study implementation based on dengue virus epidemiology. Additionally, we prepared the study protocol and supporting documents, all while ensuring smooth progress through ongoing collaboration between the client, P95, and the local team.

Our IMPACT

• The local health ministry officially approved the study
• We successfully developed a comprehensive report on the background dengue virus and arbovirus incidences
• The study is currently ongoing and is supported by strong partnerships and thorough preparation. Our strong methodological and operational support ensures the study remains on track and within budget.